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Expression and degeneration of tenascin-C in human
lung cancers
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Summary Tenascin-C is an extracellular matrix glycoprotein produced in response to epithelial-mesenchymal interactions during
organogenesis and tissue remodelling. It has therefore been proposed as a stromal marker for epithelial malignancy. To test this hypothesis,
30 human lung cancers, presenting a variety of clinicopathological features, and six specimens of normal tissue were examined by Western
and Northern blotting of tenascin-C protein and mRNA. The results obtained were: (1) elevated tenascin-C expression was detected in all 30
cases by Western blotting, with mRNA increase in 22 of them; (2) mRNA for a large isoform of tenascin-C, including an alternatively spliced
sequence, was expressed in lung cancer tissues but not in normal lungs; and (3) metastasis to lymph nodes was frequently found in cases
whose tenascin-C was degraded into small fragments. These results suggest that tenascin-C degradation can be used as a marker for
metastatic potential of a tumour.
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Tenascin-C (TN-C) (Chiquet-Ehrismann et al, 1986) is a compo-
nent of the extracellular matrix (ECM) that has been shown to be
involved in tissue interactions during fetal development and onco-
genesis. It is a glycoprotein consisting of six disulphide-linked
subunits ofmolecular sizes 190-250 kDa, with different monomer
isoforms being generated by alternative splicing (for reviews, see
Erickson and Bourdon, 1989; Jones and Copertino, 1996).
Immunohistochemical studies have revealed that TN-C appears at
specific times and locations in the embryo and also occasionally
in normal adult tissues (for a review, see Sakakura, 1995).
Subsequent to the initial proposal that it might be a stromal marker
for epithelial cancers (Mackie et al, 1987), it has been shown to be
expressed at greater levels in malignant than in benign tumours in
many organs, with a tendency for increase in advanced stages
(Bourdon et al, 1983; Anbazhagen et al, 1990; Van Eyken et al,
1990; Vollmer et al, 1990; Koukoulis et al, 1991; Sakakura et al,
1991; Borsi et al, 1992). A high-molecular-weight isoform that is
generated by alternative splicing of RNAs of TN-C was found
predominantly in breast (Borsi et al, 1992), prostatic (Ibrahim
et al, 1993) and colorectal (Hauptmann et al, 1995) cancers. The
appearance ofsuch a large TN-C isoform has been suggested to be
of significance for tumour progression. However, in lung cancers,
the results obtained so far have been anomalous. Whereas the
splicing pattern ofTN-C mRNA was found to be altered, the level
of expression was variable, with an increase but also at times a
decrease being noted (Oyama et al, 1991).
In the present study, we examined the molecular size ofTN-C in
human lung cancers using both Western and Northern blotting, in
particular concentrating on the relation to clinicopathological
features. We could demonstrate expression of a large isoform of
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TN-C mRNA in very many cases, but immunoreactive TN-C in
SDS-polyacrylamide gels demonstrated a variety ofsmaller sizes,
indicating degradation of TN-C molecules. The clinicopatholog-
ical significance ofthis degradation was therefore assessed.
MATERIALS AND METHODS
Tissues
Primary lung cancers from 30 patients who had undergone surgical
resection at Mie University Hospital or Suzuka Kaisei Hospital
between 1989 and 1991 were used in this study. The cancers were
histologically classified as 11 squamous cell carcinomas (SCCs)
and 19 adenocarcinomas. Lymph node metastasis was observed in
13 cases including five SCCs and eight adenocarcinomas. The
other 17 cases showed no metastases. Six specimens of normal
tissues either from cancer surroundings or from fresh autopsy
material confirmed subsequently by histological examination to be
free of any pathological change were used as controls. All tissues
were examined by Western blotting for TN-C protein and by
Northern and dot blotting for TN-C mRNA.
Antibodies
RCB1 rat monoclonal antibody against human TN-C (Oike et al,
1990) and biotinylated antibody for rat IgG (Vector, Burlingame,
CA, USA) were used. RCB1 recognizes an epidermal growth
factor (EGF)-like domain (personal communication by M
Kusakabe, Riken, Tsukuba).
Western blotting
Cancers and normal lungtissues werehomogenized in4 ml ofbuffer
A (20 mm Tris-HCl, 0.15 M sodium chloride, 1 M EDTA, 1 mm,
phenylmethylsulphonyl fluoride (PMSF), 1-mm dithiothreitol,
pH 7.4) per g of tissue on ice in a Polytron. The homogenates
were centrifuged at 20000g for 15 min. The precipitates were
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Figure 1 Analysis of TN-C expression in lung cancer and normal lung tissues by Western (A) and Northern (B) blotting and dot blot hybridization (C).
Lanes 1-6, cancer tissues. Lane 7, normal lung
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Figure 2 Analysis of TN-C degradation in lung cancer tissues by Western blotting. (A) Cases showing little TN-C degradation. (B) Cases showing evident
TN-C degradation
resuspended in buffer A supplemented with 2 M urea (1 ml per g of
tissue), stirred for 2 h and recentrifuged. The supernatants were
saved as urea extracts.
The urea extracts (100 jg ofprotein per lane) were subjected to
electrophoresis in 6% SDS-polyacrylamide gels according to the
method of Laemmli (1970). Immunoblotting was performed using
the procedure of Khyse-Andersen (Khyse-Andersen, 1984). The
membranes were incubated with blocking solution containing 2%
normal rabbit serum for 30 min, then with RCB1 (final concentra-
tion 3.3 mg ml-1) for 60 min, following the avidin-biotin complex
(ABC) method. Immunoreactive proteins were visualized by reac-
tion in a solution containing 0.03% (w/v) cobalt chloride, 0.04%
3,3-diaminobenzidine tetrachloride and 0.036% hydrogen peroxide.
Northern blotting and dot blot hybridization
The human TN-C cDNA clone HT24C (nucleotides 6209-7295;
Siri et al, 1991) was a kind gift from Dr Zardi, National Cancer
Research Institute, Genoa, Italy.
Total RNAs were extracted from the materials by the acid guani-
dium thiocyanate-phenol-chloroform method (Chomczynski and
Sacci, 1987), electrophoresed (10 jg per lane) in 0.8% agarose/
2.2 M formaldehyde-denaturing gels and transferred onto Hybond-
N filters (Amersham, Buckinghamshire, UK). Blotted membranes
were then hybridized with the P32-labelled TN-C probe. Fordotblot
hybridization, 5-jig aliquots of each RNA were dotted onto
Hybond-N filters and hybridized simultaneously in the same way
as for Northern blotting.
Immunohistochemistry
Tissues were fixed in phosphate-buffered paraformaldehyde with
picric acid and frozen in liquid nitrogen for cryostat sectioning.
The sections were immunostained for TN-C as described previ-
ously (Ilunga and Lriyama, 1995) using the ABC method.
RESULTS
Expression of large TN-C isoforms in lung tissues
On immunoblotting, TN-C reactive bands sized 190 kDa were
observed in all 30 ofthe lung cancers; bands sized 250 kDa, occa-
sionally accompanied by a 220-kDa band, were observed in
28 cases (Figure IA, lanes 1-6). Abundant expression of TN-C
mRNA, in comparison with normal lung was demonstrated in 22
of the 30 cases by dot blot hybridization (Figure IC, lanes 1-5).
The remaining eight cases showed no or little TN-C expression
(Figure IC, lane 6). On Northern blotting, a 7.5-kb large-size TN-
C mRNA isoform was found in 19 cases and a 5.5-kb small-size
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Table 1 TN-C in lung tissues and its degradation
Histological No. of Degradation of TN-C (%)
type cases
+
n(%) n(%)
Neoplastic
Squamous cell carcinoma 11 2 (18.2) 9 (81.8)
Adenocarcinoma 19 5 (26.3) 14 (73.7)
Normal 6 0 6 (100)
Table 2 Relation of TN-C degradation to lymph node metastasis
Lymph node No. of Degradation of TN-C (%)
metastasis cases
n(%) n(%)
+ 13 6 (46.1)a 7 (53.8)
17 1 (5.8) 16(94.1)
aSignificant positive relationi between metastasis and TN-C degradation
(P= 0.025).
isoform in 6 of the 22 cases. Normal lungs expressed only the
smaller 5.5-kb TN-C (Figure IB, lane 7). Immunoreactive TN-C
was weakly present in normal lungs at 250 and 190 kDa (Figure
IA, lane 7). The appearance of the high band TN-C molecule is
presumably caused by limited expression of the large isoform of
TN-C mRNA.
TN-C degradation in lung cancers
Cases were divided into two groups from the migrating patterns of
the TN-C molecules on the gels, one showing two or three bands at
the same heights as those ofthe controls (Figure 2A) and the other
exhibiting additional intensely labelled bands lower than 190 kDa
(Figure 2B). These bands were concluded to be generated by
degradation of TN-C. No relationship was found between the
histological type and such degradation (Table 1). In tumours
demonstrating lymph node metastasis, however, lower bands were
observed in 6 of 13 cases (46.1%), a significantly higher incidence
than in the group without metastasis (5.8%) (P = 0.025, Table 2).
Tissue distribution of TN-C demonstrated by
immunohistochemistry
Examination of 30 neoplastic tissues by TN-C immunohistochem-
istry revealed intense and diffuse staining of the fibrous stroma
surrounding the neoplastic epithelia in all tumours, regardless of
the histological and clinical features. Cases whose TN-C mole-
cules were degraded on the gels did not show any remarkable
differences from their non-degraded counterparts (Figure 3A and
B). In the six normal lung specimens, TN-C staining was positive
in the bronchial basement membrane and the vascular walls, and
was irregularly scattered on the alveolar walls (Figure 3C).
Figure 3 Immunohistochemistry of TN-C in lung cancers and normal lung.
(A) An adenocarcinoma without TN-C degradation. (B) An adenocarcinoma
with TN-C degradation. (C) Normal lung. Bar 100,gm
DISCUSSION
In the breast (Koukoulis et al, 1991; Borsi et al, 1992), prostate
(Ibrahim et al, 1993) and colorectum (Hauptmann et al, 1995),
preferential expression of higher-molecular-weight isoforms of
TN-C generated by alternative splicing ofRNAs has been observed
in cancer tissues. In this study, we demonstrated similar results for
the majority of lung cancers. Thus, a large 7.5-kb isoform was
detected in all 22 cases expressing appreciable levels of TN-C
mRNA, while in normal samples only a small 5.5-kb isoform was
found. With regard to the activity of the alternatively spliced
domain of TN-C, two papers have appeared in the literature
reporting an association with down-regulation offocal adhesion of
cells (Murphy-Ullrich et al, 1991) and stimulation of corneal cell
migration (Kaplony et al, 1991). Other studies using recombinant
fragment of human TN-C have revealed that the alternatively
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spliced domain can bind to annexin II on human endothelial cells
and promote cell migration (Chung and Erickson, 1994; Chung et
al, 1996). These findings suggest that the larger TN-C molecules
may be involved in detachment ofcells from the stroma and in cell
movement, thus affecting the malignant behaviour oftumour cells.
On the other hand, the extracellular matrix (ECM) network forms
a tough and highly crosslinked structural skeleton, which may
protect against penetration by tumour cells in the tissue. In this
regard, a crucial step in tumour invasion is degradation of ECM
proteins by proteolytic enzymes. Two papers concerned with degra-
dation of TN-C by matrix metalloproteinase (MMP) have been
published. One described the susceptibility of TN-C purified from
human melanoma cells (mainly the large isoform) to MMPs-1, -3
and -7 (Imai et al, 1994). The other reported the variation in small
and large isoforms purified from baby hamster kidney (BHK) cells
transfected with human TN-C cDNA (Siri et al, 1995). Recently,
TN-C degradation in tissue was reported by Riley et al (1996) on
Western blot analysis of TN-C extracted from normal and degen-
erate tendons. Only the small isoform was found in normal tendons,
while the large isoform was also detected with several proteolytic
fragments in degenerate tendons. Here, in lung cancers, we demon-
strated several smaller bands of TN-C on Western blots. Although
we can not rule out the possibility ofspliced variants, the absence of
any smaller transcripts than 5.5 kb on the Northern blots strongly
suggests the conclusion that these smaller bands are indeed degrada-
tion products of TN-C. As MMPs are known to be produced by
various tumour cells (Stetler-Stevenson et al, 1993), it is likely that
they are also expressed by lung cancers. The pattern of fragmenta-
tion of TN-C found in the present study thus suggests the presence
ofvarious types ofMMPs.
We found a higher frequency oflymph node metastasis in many
cases with degraded TN-C molecules. This indicates that the
amount of degraded fragments of TN-C may be related to the
degree ofdynamic remodelling ofcancer tissues. According to Siri
et al (1995), the large isoform is degraded by MMPs-2 and -3, with
cleavage occurring inside the alternatively spliced region. Thus, it
is extremely important to identify what proteolytic enzymes are
active in lung cancers and how they influence the clinicopatho-
logical behaviour.
In the present study, strong immunoreactivity was observed in
the stroma of all cases of various histological types. In normal
lungs, in contrast, weak staining was found in the bronchial base-
ment membrane and vascular walls in line with earlier findings
(Soini et al, 1993). Thus, TN-C positivity is not restricted to malig-
nant neoplasms and is not specific for the cancer tissue, as initially
proposed (Mackie et al, 1987). It rather appears to be present at
interfaces between different types of cell dynamics. Invasion
fronts clearly represent such interfaces, where cancer cells
confront host tissues. During cancer progression, preferential
expression and deposition of large isoform TN-C might bring
about changes conducive to cell movement. Deposited TN-C is
finally digested into small fragments by a variety of MMPs. As it
proved to be impossible at the immunohistochemistry level to
evaluate the extent of degradation of TN-C molecules, biochem-
ical analyses may be more useful for further clinicopathological
assessment ofthe role that this process plays in malignancy.
ABBREVIATIONS
TN-C, tenascin-C; ECM, extracellular matrix; SCC, squamous
cell carcinoma; MMP, matrix metalloproteinase
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